Structural Heart Disease: A Comprehensive Review of Pathophysiology, Advanced Diagnostic Modalities, Evolving Therapeutic Strategies, and Crucial Prognostic Implications

Many thanks to our sponsor Esdebe who helped us prepare this research report.

Abstract

Structural heart disease (SHD) represents a diverse and complex spectrum of cardiac conditions characterized by abnormalities in the fundamental anatomical components of the heart, including its valves, chambers, walls, and major blood vessels. These intricate structural anomalies can profoundly disrupt normal cardiovascular physiology, leading to a cascade of hemodynamic disturbances, progressive myocardial dysfunction, and ultimately, significant morbidity and mortality if not accurately diagnosed and optimally managed. This comprehensive and in-depth review aims to meticulously elucidate the intricate pathophysiology underlying various forms of SHD, ranging from congenital defects to acquired valvular and myocardial disorders. It will critically examine the evolution of diagnostic methodologies, encompassing both established techniques and groundbreaking emerging technologies that have revolutionized precision in assessment. Furthermore, the report will extensively discuss contemporary therapeutic modalities, spanning the continuum from sophisticated medical management to pioneering interventional cardiology procedures and advanced surgical corrections. A significant emphasis will be placed on the paramount importance of early detection and timely intervention, exploring their profound impact on improving long-term patient outcomes, enhancing quality of life, and mitigating healthcare burdens. By integrating the latest scientific advancements, robust research findings, and evolving clinical best practices, this detailed report provides an essential resource for healthcare professionals specializing in cardiovascular medicine, offering insights crucial for advanced clinical practice and ongoing research endeavors.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction: The Evolving Landscape of Structural Heart Disease

Structural heart disease (SHD) broadly encompasses a wide array of cardiac disorders defined by inherent or acquired defects or abnormalities within the heart’s intricate anatomical structure. This includes the four heart valves (aortic, mitral, tricuspid, pulmonic), the muscular walls of its chambers (atria and ventricles), the septa separating these chambers, and the great vessels that emanate from or lead into the heart, such as the aorta and pulmonary artery. These structural aberrations can lead to a spectrum of functional impairments, ranging from subtle hemodynamic disturbances to overt heart failure and life-threatening arrhythmias, underscoring their profound clinical significance. The global prevalence of SHD is substantial and growing, reflecting both an aging population and improved diagnostic capabilities. In the United States alone, heart valve disease affects approximately 2.5% of the general population, with its incidence rising sharply with age, impacting over 13% of individuals aged 75 and older (Cleveland Clinic, my.clevelandclinic.org/health/diseases/22501-structural-heart-disease). Furthermore, congenital heart conditions, representing structural abnormalities present at birth, impact a significant demographic, with estimates suggesting over 1.4 million adults and 1 million children currently living with these conditions in the United States (Cleveland Clinic, my.clevelandclinic.org/health/diseases/22501-structural-heart-disease).

Despite its considerable prevalence and potential severity, SHD often remains underdiagnosed or detected late in its progression. This delay can be attributed to its frequently insidious onset, where compensatory mechanisms may mask symptoms for years, coupled with the often non-specific nature of early clinical manifestations. This characteristic has colloquially earned SHD the moniker ‘silent scourge,’ highlighting the challenge in timely identification. However, the paradigm of SHD management has undergone a profound transformation over the past two decades, largely driven by remarkable advancements in diagnostic imaging, sophisticated transcatheter interventions, and refined surgical techniques. This evolution mandates a deeper understanding of the disease continuum, from its molecular and cellular underpinnings to its clinical presentation and the comprehensive array of available therapeutic options. The imperative for early detection and precision intervention is more critical than ever, as these factors are demonstrably linked to mitigating adverse clinical outcomes, preserving myocardial function, enhancing overall patient quality of life, and reducing the long-term societal burden of cardiovascular disease. This review aims to provide a granular and comprehensive overview of SHD, systematically exploring its multifaceted pathophysiology, the cutting-edge diagnostic advancements that facilitate its characterization, the diverse therapeutic strategies employed, and the critical role of prompt identification in shaping a more favorable prognosis for affected individuals.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Pathophysiology of Structural Heart Disease: Disruption of Cardiac Architecture and Function

The heart’s structural integrity is fundamental to its ability to efficiently pump blood throughout the body. When this intricate architecture is compromised, a cascade of pathophysiological events ensues, leading to diverse clinical syndromes. SHD can be broadly categorized into primary valvular diseases, cardiomyopathies affecting the heart muscle, and congenital heart defects present from birth, along with conditions affecting the great vessels.

2.1. Heart Valve Diseases: Disruption of Unidirectional Blood Flow

Heart valve diseases are among the most prevalent forms of SHD, characterized by dysfunctions that impede or misdirect blood flow. These dysfunctions typically manifest as either stenosis, a pathological narrowing of the valve orifice that obstructs forward blood flow, or regurgitation (insufficiency), a failure of the valve leaflets to close completely, leading to backward blood flow. Both conditions invariably increase cardiac workload and, if untreated, can culminate in myocardial remodeling, contractile dysfunction, and progressive heart failure.

2.1.1. Aortic Valve Diseases

• Aortic Stenosis (AS): This condition involves the progressive narrowing of the aortic valve orifice, obstructing blood flow from the left ventricle (LV) into the aorta. The primary etiology in developed countries is calcific degeneration, often linked to risk factors akin to atherosclerosis, while rheumatic fever remains a significant cause globally. Congenital bicuspid aortic valve (BAV), affecting 1-2% of the population, predisposes to earlier onset calcification. The chronic pressure overload imposed on the LV leads to concentric left ventricular hypertrophy (LVH), a compensatory mechanism to maintain stroke volume. Initially adaptive, this hypertrophy eventually results in impaired diastolic filling, increased myocardial oxygen demand, and susceptibility to ischemia. Over time, myocardial fibrosis develops, leading to systolic dysfunction, LV dilation, and overt heart failure (Wikipedia, en.wikipedia.org/wiki/Aortic_stenosis). Classic symptoms include exertional dyspnea, angina pectoris, and syncope.

• Aortic Regurgitation (AR): Also known as aortic insufficiency, AR occurs when the aortic valve fails to close completely during diastole, causing blood to leak back from the aorta into the LV. Etiologies include congenital abnormalities, rheumatic heart disease, infective endocarditis, aortic root dilation (e.g., Marfan syndrome, aortic dissection, hypertension), and inflammatory conditions. The LV experiences chronic volume overload, leading to eccentric hypertrophy (dilation with increased wall thickness) to accommodate the regurgitant volume and maintain forward stroke volume. This chronic overload stretches myocardial fibers, eventually leading to myocardial dysfunction, irreversible LV dilation, and heart failure. Symptoms often include exertional dyspnea, fatigue, palpitations, and in severe cases, angina or syncope.

2.1.2. Mitral Valve Diseases

• Mitral Stenosis (MS): This involves narrowing of the mitral valve orifice, obstructing blood flow from the left atrium (LA) to the LV during diastole. Rheumatic fever is the overwhelming primary cause worldwide, leading to leaflet thickening, commissural fusion, and chordal shortening. The pressure gradient across the stenotic valve leads to significant LA pressure elevation, causing LA enlargement and increasing the risk of atrial fibrillation and systemic thromboembolism. Increased LA pressure is transmitted to the pulmonary vasculature, leading to pulmonary hypertension, right ventricular (RV) failure, and symptoms like dyspnea, orthopnea, and hemoptysis.

• Mitral Regurgitation (MR): MR is characterized by the backflow of blood from the LV into the LA during systole. It can be primary (organic), due to structural abnormalities of the valve apparatus itself (e.g., degenerative myxomatous disease, prolapse, rupture of chordae tendineae, infective endocarditis, rheumatic heart disease), or secondary (functional), where the valve leaflets are structurally normal but fail to coapt due to LV remodeling (e.g., ischemic cardiomyopathy, dilated cardiomyopathy). Both forms result in LV volume overload, leading to eccentric LV hypertrophy and dilation. Chronic volume overload can lead to progressive LV dysfunction and heart failure. Patients often present with dyspnea, fatigue, and palpitations.

2.1.3. Tricuspid and Pulmonic Valve Diseases

• Tricuspid Regurgitation (TR): The most common tricuspid valve pathology, TR is usually functional, secondary to RV dilation and dysfunction (e.g., due to pulmonary hypertension, left-sided heart disease). Organic causes are less common but include rheumatic fever, endocarditis (especially in intravenous drug users), and congenital defects. TR leads to right atrial (RA) and systemic venous congestion, resulting in symptoms like peripheral edema, ascites, and hepatic congestion.

• Pulmonic Stenosis (PS): Predominantly a congenital defect, PS involves narrowing of the pulmonic valve, obstructing blood flow from the RV into the pulmonary artery. This causes RV pressure overload, leading to RV hypertrophy. Severe PS can lead to RV failure. Symptoms include dyspnea, fatigue, and syncope, though mild cases may be asymptomatic.

2.2. Cardiomyopathies: Diseases of the Heart Muscle

Cardiomyopathies are a group of diseases affecting the myocardium (heart muscle), impairing its ability to contract and/or relax effectively, leading to mechanical and/or electrical dysfunction. They are classified based on their functional characteristics and underlying pathophysiology.

2.2.1. Hypertrophic Cardiomyopathy (HCM)

HCM is a genetic disorder, typically inherited in an autosomal dominant pattern, characterized by abnormal thickening (hypertrophy) of the heart muscle, often asymmetrical and predominantly affecting the interventricular septum. This hypertrophy can obstruct blood flow from the LV (left ventricular outflow tract obstruction, LVOTO), particularly during systole. The myocardial disarray, fibrosis, and impaired diastolic relaxation contribute to increased myocardial stiffness, elevated filling pressures, and reduced ventricular compliance. HCM is a leading cause of sudden cardiac death in young athletes due to ventricular arrhythmias, often triggered by myocardial ischemia and fibrosis. Symptoms include dyspnea, chest pain, syncope, and palpitations (Yale Medicine, www.yalemedicine.org/conditions/structural-heart-disease).

2.2.2. Dilated Cardiomyopathy (DCM)

DCM is characterized by enlargement and weakening of the heart muscle, leading to impaired systolic function and significant dilation of one or both ventricles. It is the most common form of cardiomyopathy and a frequent cause of heart failure. Etiologies are diverse, including genetic mutations (e.g., in genes encoding sarcomeric proteins, cytoskeletal proteins), viral infections (e.g., myocarditis), alcohol abuse, toxins, chemotherapy agents, peripartum cardiomyopathy, and prolonged arrhythmias. The progressive ventricular dilation and reduced contractility lead to reduced cardiac output and activation of neurohormonal compensatory mechanisms, which paradoxically contribute to further adverse remodeling. Symptoms include progressive dyspnea, fatigue, edema, and symptoms of systemic congestion.

2.2.3. Restrictive Cardiomyopathy (RCM)

RCM is the least common type of cardiomyopathy, characterized by rigid ventricular walls that impede diastolic filling, leading to high filling pressures despite normal or near-normal systolic function and chamber dimensions. The myocardium becomes stiff and non-compliant due to infiltration (e.g., amyloidosis, sarcoidosis, hemochromatosis) or fibrosis (e.g., radiation-induced, idiopathic fibrosis). This leads to biatrial enlargement and signs of biventricular heart failure. Prognosis is often poor, and treatment is challenging, focusing on managing symptoms and the underlying cause if possible.

2.2.4. Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)

ARVC is a genetic disorder primarily affecting the right ventricle, characterized by progressive fibrofatty replacement of myocardial tissue. This structural abnormality creates substrates for life-threatening ventricular arrhythmias, particularly ventricular tachycardia, and can lead to sudden cardiac death, especially during exercise. It is often caused by mutations in genes encoding desmosomal proteins, crucial for cell-to-cell adhesion in the myocardium. Over time, RV dysfunction and dilation can develop, sometimes progressing to involve the left ventricle.

2.3. Congenital Heart Defects (CHDs): Anomalies Present at Birth

Congenital heart defects are structural abnormalities of the heart or great vessels that are present at birth, resulting from errors in cardiac development during gestation. These defects can range from simple, isolated lesions to complex malformations involving multiple cardiac structures. While often diagnosed in infancy or childhood, many individuals with complex CHDs are now surviving into adulthood, requiring specialized care (National Center for Biotechnology Information, www.ncbi.nlm.nih.gov/books/NBK525139/).

2.3.1. Acyanotic Congenital Heart Defects (Left-to-Right Shunt)

These defects typically involve a shunt of oxygenated blood from the left side of the heart to the right side, increasing pulmonary blood flow. Patients usually do not present with cyanosis initially, though long-standing, uncorrected shunts can lead to pulmonary hypertension and shunt reversal (Eisenmenger syndrome), causing cyanosis.

• Atrial Septal Defect (ASD): A hole in the interatrial septum, allowing blood to shunt from the LA to the RA. This leads to right heart volume overload, resulting in RA and RV enlargement and increased pulmonary blood flow. Symptoms may be absent for decades, but exertional dyspnea, fatigue, arrhythmias (e.g., atrial fibrillation), and pulmonary hypertension can develop in adulthood.

• Ventricular Septal Defect (VSD): A hole in the interventricular septum, allowing blood to shunt from the LV to the RV. The magnitude of the shunt depends on the size of the defect and pulmonary vascular resistance. Small VSDs may be asymptomatic and close spontaneously. Larger VSDs lead to significant left-to-right shunting, causing LV and LA volume overload, increased pulmonary blood flow, and eventually pulmonary hypertension and heart failure. Symptoms include dyspnea, poor feeding in infants, and growth failure.

• Patent Ductus Arteriosus (PDA): Persistence of the fetal ductus arteriosus, a blood vessel connecting the aorta and pulmonary artery. In postnatal life, a PDA allows blood to shunt from the higher-pressure aorta to the lower-pressure pulmonary artery. This results in pulmonary overcirculation, leading to LV volume overload and potentially pulmonary hypertension and heart failure. Patients may present with a continuous ‘machinery’ murmur, dyspnea, and poor weight gain in infancy.

• Coarctation of the Aorta (CoA): A localized narrowing of the aorta, typically distal to the left subclavian artery. This obstruction leads to increased pressure proximal to the coarctation (upper extremities, head) and reduced pressure distally (lower extremities). Symptoms can include hypertension in the upper body, diminished femoral pulses, claudication, and in severe cases, heart failure in infancy. Long-term complications include hypertension, aortic aneurysm/dissection, and cerebral aneurysms.

• Bicuspid Aortic Valve (BAV): The most common congenital heart anomaly, characterized by an aortic valve with two cusps instead of the normal three. While initially functional, BAV is prone to earlier calcification, stenosis, or regurgitation in adulthood. It is also associated with ascending aortic dilation and dissection risk.

2.3.2. Cyanotic Congenital Heart Defects (Right-to-Left Shunt)

These complex defects involve a shunt of deoxygenated blood from the right side of the heart to the left, bypassing the lungs, leading to reduced systemic oxygen saturation and cyanosis (bluish discoloration of skin and mucous membranes).

• Tetralogy of Fallot (TOF): The most common cyanotic CHD, defined by four classic anomalies: ventricular septal defect, pulmonic stenosis, overriding aorta (aorta arises from both ventricles), and right ventricular hypertrophy. The severity of cyanosis depends on the degree of pulmonic stenosis. Patients may experience ‘tet spells’ (paroxysmal episodes of severe cyanosis and hypoxia). Surgical correction is typically performed in infancy.

• Transposition of the Great Arteries (TGA): A condition where the aorta arises from the RV and the pulmonary artery from the LV, creating two parallel, independent circulations. This is incompatible with life unless there is mixing of oxygenated and deoxygenated blood through shunts (e.g., PDA, PFO, VSD). Profound cyanosis is present from birth, requiring immediate intervention.

• Hypoplastic Left Heart Syndrome (HLHS): A severe, often lethal, complex CHD characterized by underdevelopment of the left side of the heart, including the LV, aorta, aortic valve, and mitral valve. Survival is dependent on a PDA for systemic blood flow and an ASD for left atrial decompression. This condition requires staged surgical palliation or heart transplantation.

2.4. Diseases of the Great Vessels: Aorta and Pulmonary Artery

Abnormalities in the great vessels can also be classified as SHD, as they directly impact cardiac function and systemic circulation.

• Aortic Aneurysms and Dissections: Aneurysms are localized dilations of the aorta (thoracic or abdominal) resulting from weakening of the aortic wall. Dissections involve a tear in the inner layer of the aorta, allowing blood to surge between the layers, creating a false lumen. Both conditions are life-threatening and associated with hypertension, Marfan syndrome, Ehlers-Danlos syndrome, and BAV. They can lead to acute organ ischemia, rupture, and profound hemodynamic instability.

• Pulmonary Artery Hypertension (PAH): While often secondary to left-sided heart disease or chronic lung disease, primary PAH involves intrinsic structural changes within the pulmonary arteries, leading to increased resistance to blood flow and progressive RV failure. PAH can also be a long-term complication of uncorrected CHDs with left-to-right shunts (Eisenmenger syndrome).

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Risk Factors and Epidemiology: Understanding the Burden of SHD

The prevalence and incidence of SHD are influenced by a complex interplay of genetic predispositions, environmental factors, and comorbidities. Understanding these factors is crucial for prevention, early detection, and public health strategies.

3.1. General Risk Factors for Acquired SHD

• Age: Advancing age is the most significant risk factor for degenerative valvular heart diseases, particularly aortic stenosis and mitral regurgitation, due to cumulative wear and tear, calcification, and fibrotic changes over time.
• Atherosclerotic Risk Factors: Hypertension, hyperlipidemia, diabetes mellitus, obesity, and smoking are strongly associated with calcific aortic valve disease, similar to their role in coronary artery disease. These factors contribute to chronic inflammation, endothelial dysfunction, and lipid deposition within valve leaflets.
• Rheumatic Fever: Despite declining incidence in developed nations, rheumatic fever remains a major cause of valvular heart disease (especially mitral stenosis and aortic valve disease) in developing countries, stemming from untreated Streptococcus pyogenes infections.
• Infective Endocarditis: Bacterial or fungal infection of the heart valves or endocardium can lead to valve leaflet destruction, perforation, or vegetation formation, causing severe regurgitation or stenosis, and embolic events. Risk factors include intravenous drug use, prosthetic heart valves, and pre-existing valvular heart disease.
• Connective Tissue Disorders: Conditions like Marfan syndrome, Ehlers-Danlos syndrome, and Loeys-Dietz syndrome predispose individuals to aortic root dilation, aortic dissection, and valvular prolapse due to inherent weakness of connective tissues.
• Kidney Disease: Chronic kidney disease is associated with accelerated calcific valvular disease and other cardiovascular complications.
• Radiation Exposure: Mediastinal radiation therapy for cancers (e.g., Hodgkin’s lymphoma) can lead to accelerated valvular calcification and myocardial fibrosis years after treatment.

3.2. Genetic Predisposition

Genetic factors play a substantial role in many forms of SHD. Cardiomyopathies, particularly HCM and DCM, often have a strong genetic basis, with specific gene mutations identified. Many CHDs also have genetic components, though they are often multifactorial. Familial valvular diseases, like bicuspid aortic valve, also show Mendelian inheritance patterns.

3.3. Global Epidemiology

The global burden of SHD is considerable. While degenerative valve disease is predominant in high-income countries, rheumatic heart disease remains a leading cause of cardiovascular morbidity and mortality in low- and middle-income countries, highlighting significant disparities in healthcare access and public health interventions. Congenital heart defects affect approximately 1 in 100 live births worldwide, posing a significant public health challenge given improved survival rates into adulthood.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Clinical Manifestations: Recognizing the Subtle to Severe Symptoms

The clinical presentation of SHD is highly variable, depending on the specific structural anomaly, its severity, the rate of progression, and the presence of compensatory mechanisms or comorbidities. Symptoms often emerge subtly and progress insidiously, making early diagnosis challenging.

4.1. Common Symptoms of SHD

• Dyspnea (Shortness of Breath): The most common symptom, initially occurring with exertion (exertional dyspnea), then progressing to dyspnea at rest, orthopnea (dyspnea when lying flat), and paroxysmal nocturnal dyspnea (PND, sudden awakenings due to breathlessness). This reflects increased pulmonary venous pressure due to impaired ventricular filling or forward flow.
• Fatigue and Weakness: Due to reduced cardiac output and impaired oxygen delivery to peripheral tissues, especially during exertion.
• Chest Pain (Angina Pectoris): Can occur in valvular heart disease (e.g., aortic stenosis due to increased myocardial oxygen demand from LVH and reduced coronary perfusion), hypertrophic cardiomyopathy (due to myocardial ischemia), or in the context of coronary artery disease.
• Syncope or Presyncope (Fainting or Near-Fainting): Often exertional, particularly in conditions with fixed outflow obstruction (e.g., severe aortic stenosis, hypertrophic cardiomyopathy), due to inadequate cerebral perfusion during increased cardiac demand.
• Palpitations: Awareness of one’s heartbeat, often described as racing, pounding, or skipped beats. This can be a sign of arrhythmias (e.g., atrial fibrillation in mitral valve disease or HCM, ventricular arrhythmias in HCM or ARVC).
• Peripheral Edema and Ascites: Swelling in the ankles, legs, or abdomen due to fluid retention caused by right-sided heart failure and systemic venous congestion.
• Cyanosis: Bluish discoloration of the skin and mucous membranes, characteristic of cyanotic congenital heart defects where deoxygenated blood bypasses the lungs.
• Cough: Can be related to pulmonary congestion or compression of airways by an enlarged heart or great vessels.

4.2. Physical Examination Findings

A thorough physical examination is invaluable in raising suspicion for SHD and guiding further diagnostic workup.

• Heart Murmurs: Auscultation of characteristic heart murmurs is a hallmark of valvular heart disease and many CHDs. Their timing (systolic, diastolic, continuous), location, radiation, pitch, and quality provide clues to the underlying defect.
• Palpation: Abnormal thrills (palpable murmurs), displaced or sustained apical impulses (indicating LVH or dilation), or palpable RV heave (indicating RVH) can be detected.
• Jugular Venous Distension (JVD): Elevated JVP suggests increased right atrial pressure and right heart failure.
• Peripheral Signs: Pulsus parvus et tardus (small and delayed pulse) in severe AS, wide pulse pressure in AR, differential pulses or blood pressure in CoA.
• Lung Auscultation: Rales or crackles indicate pulmonary congestion.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Diagnostic Pathways: From Initial Assessment to Precision Imaging

Accurate diagnosis and comprehensive characterization of SHD are paramount for effective management. The diagnostic process typically involves a stepwise approach, starting with clinical assessment and progressing to advanced imaging techniques.

5.1. Initial Clinical Assessment

• Detailed History Taking: Eliciting symptoms, their progression, family history of heart disease, and relevant medical comorbidities (e.g., rheumatic fever, hypertension, diabetes).
• Thorough Physical Examination: Including vital signs, cardiac auscultation for murmurs, palpation of pulses and precordium, assessment of jugular venous pressure, and signs of fluid overload.
• Electrocardiography (ECG): A readily available and non-invasive tool that records the heart’s electrical activity. While non-diagnostic for specific structural defects, ECG can provide crucial clues such as signs of chamber enlargement (e.g., left ventricular hypertrophy in AS, right ventricular hypertrophy in pulmonary hypertension), conduction abnormalities, or arrhythmias (e.g., atrial fibrillation, ventricular tachycardia) that are commonly associated with SHD (Memorial Hermann, memorialhermann.org/services/conditions/structural-heart-disease-and-interventional-cardiology).

5.2. Traditional Diagnostic Methods: The Cornerstone of Evaluation

• Echocardiography (Transthoracic and Transesophageal): This is the cornerstone and primary diagnostic modality for nearly all forms of SHD. Utilizing ultrasound waves, echocardiography provides real-time, non-invasive visualization of cardiac structures and dynamic assessment of blood flow.

  • Transthoracic Echocardiography (TTE): Provides comprehensive assessment of valve morphology and function (leaflet thickening, calcification, prolapse, regurgitant jets, stenosis severity via Doppler gradients), chamber dimensions and volumes, ventricular wall thickness, systolic and diastolic function (ejection fraction, diastolic parameters), and pericardial integrity. It can identify shunts, estimate pulmonary artery pressures, and evaluate prosthetic valves.
  • Transesophageal Echocardiography (TEE): Involves inserting a small transducer into the esophagus, providing superior, high-resolution images by minimizing interference from lung and chest wall. TEE is invaluable for detailed assessment of valve anatomy (e.g., guiding mitral valve repair, assessing vegetations in endocarditis), identifying subtle septal defects, detecting thrombi in the left atrium, and guiding interventional procedures (e.g., TAVR, MitraClip).
  • Stress Echocardiography: Performed during exercise or pharmacological stress (e.g., dobutamine), it assesses valvular gradients and LV function under stress, useful for unmasking symptoms or evaluating true severity in low-flow, low-gradient AS.

• Cardiac Catheterization: An invasive procedure involving the insertion of a catheter into the heart chambers and great vessels, typically via femoral or radial artery/vein.

  • Diagnostic Catheterization: Allows precise measurement of intracardiac pressures (e.g., pulmonary artery pressure, LV end-diastolic pressure, valve gradients), assessment of cardiac output, and visualization of coronary arteries via angiography. It is critical for confirming severe valvular disease, quantifying shunts in CHDs, and assessing coronary artery disease prior to surgical or interventional SHD procedures (Memorial Hermann, memorialhermann.org/services/conditions/structural-heart-disease-and-interventional-cardiology).
  • Interventional Catheterization: Many SHD treatments are performed through catheterization (see Section 6.2).

5.3. Advanced Imaging Techniques: Precision and Detail

Advancements in imaging technology have significantly enhanced the accuracy and comprehensiveness of SHD diagnosis, particularly in cases where echocardiography may be limited or where more detailed anatomical and functional assessment is required.

• Cardiac Magnetic Resonance Imaging (CMRI): Considered the ‘gold standard’ for comprehensive assessment of cardiac structure and function due to its superior spatial resolution and tissue characterization capabilities, without radiation exposure. CMRI excels in:

  • Precise quantification of ventricular volumes, mass, and ejection fraction.
  • Detailed evaluation of myocardial tissue characteristics, including fibrosis (late gadolinium enhancement, LGE), edema, and fat infiltration, crucial for diagnosing and risk-stratifying cardiomyopathies (e.g., HCM, DCM, ARVC, myocarditis, amyloidosis).
  • Accurate assessment of valve regurgitation severity via phase-contrast flow quantification.
  • Detailed anatomical imaging of complex congenital heart defects and great vessel abnormalities (e.g., aortic aneurysms, dissections) (Mayo Clinic, www.mayo.edu/research/centers-programs/cardiovascular-research-center/research/structural-heart-disease-program).

• Cardiac Computed Tomography (CCT): Offers high-resolution anatomical imaging, particularly valuable for pre-procedural planning for transcatheter interventions and evaluation of the great vessels. Key applications include:

  • Coronary CT Angiography (CCTA): For non-invasive assessment of coronary artery disease, particularly in patients undergoing TAVR to rule out significant coronary stenoses.
  • Pre-TAVR Planning: Precise measurements of aortic annulus size, valve calcification, and vascular access routes, essential for device sizing and delivery.
  • Evaluation of Great Vessels: Detailed imaging of aortic aneurysms, dissections, and congenital anomalies of the great arteries (Mayo Clinic, www.mayo.edu/research/centers-programs/cardiovascular-research-center/research/structural-heart-disease-program).
  • Pulmonary Vein Anatomy: Crucial for planning atrial fibrillation ablation procedures.

• Nuclear Cardiology (SPECT/PET): While less frequently used for primary SHD diagnosis, these techniques are valuable for:

  • Myocardial Viability Assessment: In ischemic cardiomyopathy, to determine if revascularization will improve function.
  • Cardiac Amyloidosis: Technetium pyrophosphate (PYP) scintigraphy for transthyretin amyloid cardiomyopathy (ATTR-CM) diagnosis.
  • Myocardial Perfusion Imaging: Assessing ischemia, particularly in conjunction with exercise or pharmacological stress.

5.4. Emerging Diagnostic Techniques and Biomarkers

• Biomarkers: Blood tests measuring specific molecules released by the heart provide complementary diagnostic and prognostic information.
  • Natriuretic Peptides (NT-proBNP, BNP): Elevated levels indicate myocardial stretch and increased wall stress, strongly correlated with heart failure severity and prognosis in valvular heart disease and cardiomyopathies. They are useful for screening, diagnosis, and monitoring treatment effectiveness.
  • High-Sensitivity Troponins: Indicate myocardial injury, useful in acute decompensated heart failure or for identifying patients with underlying ischemia.
  • Inflammatory Markers: (e.g., CRP) may be elevated in conditions like myocarditis or endocarditis.
• Artificial Intelligence (AI) and Machine Learning (ML): These technologies are revolutionizing diagnostic cardiology by enhancing image analysis, risk stratification, and predicting outcomes. AI algorithms can analyze vast amounts of echocardiographic, CMRI, and CCT data to detect subtle abnormalities, automate measurements, and assist in complex diagnoses (Mayo Clinic, www.mayo.edu/research/centers-programs/cardiovascular-research-center/research/structural-heart-disease-program). They hold promise for personalized medicine by integrating clinical, imaging, and genomic data to predict individual patient responses to therapy.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Treatment Modalities: A Spectrum of Approaches

The management of SHD is increasingly individualized, moving towards a multidisciplinary heart team approach that integrates medical, interventional, and surgical strategies to optimize patient outcomes. The choice of therapy depends on the specific diagnosis, severity, patient symptoms, comorbidities, age, and overall risk profile.

6.1. Medical Management: Symptom Control and Disease Progression Mitigation

Pharmacological therapies play a crucial role in managing symptoms, preventing disease progression, and supporting the heart, especially for patients not yet candidates for intervention or as adjunctive therapy post-procedure. They aim to reduce cardiac workload, control heart rate and rhythm, improve myocardial contractility, and manage fluid retention (Apollo 247, www.apollo247.com/health-topics/heart-disease/structural-heart-disease).

• Diuretics (e.g., Furosemide, Torsemide): Used to alleviate symptoms of fluid overload (dyspnea, edema) by promoting urine excretion, thereby reducing preload and pulmonary/systemic congestion.
• Angiotensin-Converting Enzyme (ACE) Inhibitors / Angiotensin Receptor Blockers (ARBs): Essential for managing heart failure with reduced ejection fraction and hypertension. They reduce afterload, improve cardiac remodeling, and decrease mortality.
• Beta-Blockers (e.g., Metoprolol, Carvedilol): Reduce heart rate, improve diastolic filling, decrease myocardial oxygen demand, and are beneficial in various cardiomyopathies (DCM, HCM) and heart failure. They are also used for rate control in atrial fibrillation.
• Aldosterone Antagonists (e.g., Spironolactone, Eplerenone): Used in heart failure to reduce myocardial fibrosis and improve outcomes.
• Vasodilators (e.g., Nitrates, Hydralazine): May reduce symptoms in certain conditions by decreasing preload and/or afterload.
• Anticoagulation (e.g., Warfarin, DOACs): Crucial for preventing thromboembolic events in patients with atrial fibrillation, mechanical prosthetic valves, or significant left atrial enlargement/stasis.
• Rhythm Control Medications / Antiarrhythmics: Used to manage arrhythmias like atrial fibrillation or ventricular arrhythmias, which are common complications of SHD.
• Disease-Specific Medications: For instance, in hypertrophic cardiomyopathy, beta-blockers or calcium channel blockers are used to reduce LVOT obstruction and improve diastolic function. In pulmonary hypertension, specific vasodilators targeting the pulmonary vasculature (e.g., endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostacyclin analogues) are used.

6.2. Interventional Procedures: Minimally Invasive Solutions

Transcatheter interventions have revolutionized the treatment of many SHD conditions, offering less invasive alternatives to traditional open-heart surgery, particularly benefiting elderly or high-risk patients. These procedures are performed in a cardiac catheterization laboratory, typically involving a small incision and guided by imaging.

• Transcatheter Aortic Valve Replacement (TAVR) / Implantation (TAVI): A landmark advancement for severe aortic stenosis, particularly for intermediate-to-high surgical risk patients, and increasingly considered for lower-risk individuals. A new aortic valve (typically bovine or porcine tissue) is delivered via a catheter (usually transfemoral) and deployed within the diseased native valve, pushing aside the calcified leaflets. TAVR avoids sternotomy and cardiopulmonary bypass, leading to faster recovery times and reduced perioperative complications compared to surgical aortic valve replacement (SAVR) (PubMed, pubmed.ncbi.nlm.nih.gov/30955999/). Key considerations include patient selection, precise valve sizing, and managing potential complications such as paravalvular leak, vascular complications, and conduction disturbances.

• Transcatheter Mitral Valve Repair (TMVr):

  • MitraClip™ System: The most established TMVr device, used to treat severe primary or secondary mitral regurgitation by grasping the anterior and posterior mitral valve leaflets to create a double orifice, thereby reducing regurgitation. It is indicated for symptomatic patients with severe MR who are deemed high-risk for conventional surgery (Memorial Hermann, memorialhermann.org/services/conditions/structural-heart-disease-and-interventional-cardiology).
  • Other Transcatheter Mitral Valve Interventions: Other edge-to-edge repair devices (e.g., PASCAL™), annuloplasty devices, and rapidly developing transcatheter mitral valve replacement (TMVR) systems are emerging for patients unsuitable for repair or conventional surgery.

• Transcatheter Pulmonary Valve Implantation (TPVI): Primarily used in adults and children with congenital heart disease who have previously undergone right ventricular outflow tract (RVOT) reconstruction for conditions like Tetralogy of Fallot. It allows replacement of a dysfunctional pulmonic valve without repeat open-heart surgery.

• Transcatheter Tricuspid Valve Interventions: A rapidly evolving field, with devices similar to MitraClip (e.g., TriClip™) and novel annuloplasty or replacement systems being developed for severe tricuspid regurgitation, especially in high-risk patients with progressive right heart failure.

• Percutaneous Septal Defect Closure:

  • Atrial Septal Defect (ASD) Closure: Many secundum ASDs can be closed using a catheter-delivered occluder device, avoiding open-heart surgery. This prevents chronic right heart volume overload and complications like paradoxical embolization.
  • Patent Foramen Ovale (PFO) Closure: Increasingly performed in patients with cryptogenic stroke and a PFO, to prevent recurrent embolic events.
  • Ventricular Septal Defect (VSD) Closure: Certain types of VSDs (e.g., perimembranous, muscular) can be closed percutaneously.

• Left Atrial Appendage Occlusion (LAAO): For patients with non-valvular atrial fibrillation who are at high risk for stroke but have contraindications to long-term oral anticoagulation, devices like the Watchman™ are implanted to seal off the left atrial appendage, a common source of thrombus formation.

• Alcohol Septal Ablation (ASA): A non-surgical option for symptomatic obstructive hypertrophic cardiomyopathy. A small amount of alcohol is injected into a septal perforator branch of the left anterior descending coronary artery, causing a controlled myocardial infarction in the hypertrophied septum, reducing the outflow tract obstruction.

6.3. Surgical Interventions: Traditional and Advanced Approaches

Despite the rise of transcatheter therapies, conventional cardiac surgery remains essential for many complex SHD cases, particularly for younger patients, those with concomitant conditions requiring surgery (e.g., coronary artery bypass grafting), or when transcatheter options are not suitable.

• Valve Repair and Replacement:

  • Surgical Aortic Valve Replacement (SAVR): The traditional open-heart surgery for severe aortic stenosis or regurgitation, involving sternotomy and cardiopulmonary bypass to replace the diseased valve with a mechanical or bioprosthetic valve. It remains the preferred option for younger, low-risk patients.
  • Mitral Valve Repair (MVr) vs. Mitral Valve Replacement (MVR): Surgical mitral valve repair is generally preferred over replacement for mitral regurgitation whenever feasible, as it preserves the native valve apparatus and ventricular function, avoiding the need for lifelong anticoagulation (in most cases). MVR involves replacing the valve with a mechanical or bioprosthetic valve. Surgical approaches can be conventional sternotomy or minimally invasive (e.g., thoracoscopy).
  • Tricuspid Valve Surgery: Typically performed for severe tricuspid regurgitation, often in conjunction with left-sided valve surgery. Repair (e.g., annuloplasty) is usually favored over replacement.
  • Pulmonic Valve Surgery: Primarily for congenital pulmonic stenosis or replacement after previous surgery for complex congenital heart disease.
  • Prosthetic Valve Choice: Mechanical valves are durable but require lifelong anticoagulation due to thrombogenicity. Bioprosthetic (tissue) valves are less thrombogenic but have limited durability, often requiring re-intervention after 10-15 years, making them suitable for older patients or those with contraindications to anticoagulation.

• Septal Defect Closure: Larger or more complex atrial septal defects (e.g., primum ASDs) and many ventricular septal defects still require open surgical repair, involving direct closure or patch repair.

• Coronary Artery Bypass Grafting (CABG): Often performed concomitantly with valve surgery in patients with significant coronary artery disease.

• Cardiomyopathy Surgery:

  • Septal Myectomy: For symptomatic obstructive HCM, this open-heart surgical procedure involves excising a portion of the hypertrophied septum to relieve LVOT obstruction. It offers highly effective and durable relief of symptoms.
  • Ventricular Assist Devices (VADs): Mechanical pumps surgically implanted to support the failing heart, either as a bridge to transplantation or as destination therapy for patients ineligible for transplant.
  • Heart Transplantation: The ultimate therapy for end-stage heart failure refractory to all other treatments, including severe cardiomyopathy.

• Great Vessel Surgery: Surgical repair or replacement of aortic aneurysms (e.g., Marfan syndrome, bicuspid aortopathy) and acute aortic dissections remains a critical life-saving intervention.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Long-Term Patient Management and Prognostic Implications: Ensuring Enduring Health

Long-term management of SHD extends beyond acute intervention and requires a comprehensive, patient-centered approach focused on regular monitoring, lifestyle modifications, continuous education, and psychosocial support. These elements are crucial for optimizing long-term outcomes, preventing complications, and enhancing overall quality of life.

7.1. Regular Monitoring and Follow-up

Consistent clinical surveillance is essential to evaluate disease progression, assess the efficacy of interventions, and detect potential complications. This typically includes:

• Periodic Clinical Assessments: Regular visits to a cardiologist to monitor symptoms, conduct physical examinations, and review medication adherence.
• Serial Echocardiography: To assess ventricular function, valve integrity (native or prosthetic), and detect any progression of the underlying condition or development of new issues.
• Functional Capacity Assessment: Including 6-minute walk tests or cardiopulmonary exercise testing to objectively measure exercise tolerance and functional status.
• Biomarker Monitoring: Regular measurement of natriuretic peptides (e.g., NT-proBNP) to track heart failure status and guide medical therapy adjustments.
• Arrhythmia Surveillance: Use of Holter monitors or implantable loop recorders for patients at risk of arrhythmias, particularly those with cardiomyopathies or significant chamber enlargement.
• Imaging for Prosthetic Valves: Follow-up imaging for prosthetic valves, especially mechanical valves, to ensure proper function and detect potential issues like thrombosis or pannus formation. (Virginia Mason Franciscan Health, www.vmfh.org/our-services/center-for-cardiovascular-health/structural-heart/diagnosis-treatment-structural-heart-conditions).

7.2. Lifestyle Modifications: A Foundation for Cardiac Health

Adoption and adherence to heart-healthy lifestyle practices are fundamental for managing SHD, slowing disease progression, and improving overall well-being. These recommendations are often reinforced through cardiac rehabilitation programs.

• Balanced Nutrition: Emphasizing a diet rich in fruits, vegetables, whole grains, and lean proteins, similar to the DASH (Dietary Approaches to Stop Hypertension) diet. Strict sodium restriction is crucial for managing fluid retention in heart failure.
• Regular Physical Activity: Tailored exercise programs, often initiated through cardiac rehabilitation, improve functional capacity, reduce symptoms, and enhance cardiovascular fitness. The type and intensity of exercise must be individualized based on the specific SHD and its severity.
• Smoking Cessation: Quitting smoking is paramount to reducing cardiovascular risk and improving overall health. Smoking exacerbates atherosclerosis and can worsen valvular disease progression.
• Weight Management: Maintaining a healthy body weight reduces cardiac workload and improves metabolic health, crucial for patients with SHD and comorbidities like diabetes or hypertension.
• Stress Management: Chronic stress can adversely affect cardiovascular health. Techniques such as mindfulness, meditation, and adequate sleep can be beneficial.
• Alcohol Moderation: Excessive alcohol intake can contribute to dilated cardiomyopathy and arrhythmias; moderation or abstinence is often recommended.

7.3. Patient Education and Shared Decision-Making

Empowering patients with comprehensive knowledge about their condition is vital. This involves:

• Understanding the Disease: Educating patients about their specific SHD, its natural history, and potential complications.
• Treatment Adherence: Explaining the rationale for prescribed medications and emphasizing the importance of consistent adherence.
• Symptom Recognition: Teaching patients to recognize warning signs of worsening heart failure or other complications, prompting timely medical attention.
• Prophylaxis: Educating about infective endocarditis prophylaxis in specific high-risk scenarios (e.g., prosthetic valves, certain congenital heart defects) before dental or surgical procedures.
• Shared Decision-Making: Engaging patients and their families in discussions about treatment options, risks, and benefits, ensuring their values and preferences are considered in complex decisions, particularly regarding invasive procedures (Baptist Health, www.baptist-health.com/services/heart-health/preventative-treatments/structural-heart-disease-treatment).

7.4. Psychosocial Support

Living with a chronic cardiac condition like SHD can have significant psychological and social impacts. Addressing anxiety, depression, and social isolation through counseling, support groups, and mental health interventions is an integral part of comprehensive care.

7.5. Genetic Counseling

For inherited forms of SHD (e.g., HCM, DCM, ARVC, some CHDs), genetic counseling and cascade screening of family members are crucial for early detection, risk stratification, and informed family planning.

7.6. Prognostic Implications: The Value of Early Detection

Early detection and timely intervention are unequivocally linked to improved prognosis and prevention of irreversible myocardial damage. The ‘silent’ nature of many SHD conditions means that by the time symptoms become debilitating, significant and often irreversible cardiac remodeling may have occurred.

• Improved Survival and Prognosis: Prompt diagnosis allows for initiation of medical therapies to slow progression, and timely intervention (surgical or transcatheter) can prevent or reverse adverse remodeling, preserve ventricular function, and significantly reduce the risk of heart failure, arrhythmias, and sudden cardiac death. For instance, symptomatic severe aortic stenosis carries a poor prognosis (2-3 years average survival) without intervention, which improves dramatically with timely valve replacement (Wikipedia, en.wikipedia.org/wiki/Aortic_stenosis).
• Enhanced Quality of Life: Early intervention can alleviate debilitating symptoms (dyspnea, fatigue, chest pain), restore functional capacity, and improve overall physical and mental well-being, allowing patients to maintain an active and fulfilling life.
• Prevention of Complications: Timely correction of defects can prevent long-term complications such as pulmonary hypertension, atrial fibrillation, systemic emboli, and irreversible myocardial damage.
• Cost-Effectiveness: While acute interventions may seem costly, preventing advanced heart failure and recurrent hospitalizations through early and effective management can lead to significant long-term healthcare cost savings.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

8. Challenges and Future Directions: Pushing the Frontiers of SHD Management

Despite remarkable progress, several challenges remain in the field of SHD, driving ongoing research and innovation.

8.1. Challenges

• Early Detection in Asymptomatic Patients: Identifying SHD before symptom onset remains difficult, especially for conditions with a long asymptomatic phase. Improved screening tools and AI-driven diagnostic approaches are needed.
• Risk Stratification and Timing of Intervention: Precisely identifying which asymptomatic patients will benefit from early intervention versus watchful waiting remains an area of active research, balancing the risks of intervention against the risks of delayed treatment.
• Device Durability and Long-Term Outcomes: While transcatheter devices have shown excellent short-to-mid-term outcomes, their long-term durability, especially in younger patients, requires ongoing investigation.
• Management of Complex Multi-Valvular Disease: Patients often present with disease affecting multiple valves, posing complex treatment decisions.
• Global Health Disparities: Access to advanced diagnostic tools and interventional therapies remains highly inequitable worldwide, particularly for conditions like rheumatic heart disease.

8.2. Future Directions

• Personalized Medicine: Integrating genomic, proteomic, and clinical data with AI to predict disease progression, stratify risk with greater precision, and tailor treatment strategies to individual patients.
• Advanced Imaging Beyond Anatomy: Developing imaging techniques that provide deeper insights into myocardial tissue characterization, mechanics, and molecular pathways (e.g., cardiac elastography, advanced strain imaging, metabolic imaging).
• Next-Generation Transcatheter Therapies: Development of new, more durable, and versatile transcatheter devices for all four heart valves, expanding indications to younger and lower-risk patients, and addressing more complex anatomies. This includes transcatheter mitral and tricuspid valve replacement technologies.
• Regenerative Medicine and Tissue Engineering: Research into using stem cells, gene therapy, or bio-engineered scaffolds to repair or regenerate damaged cardiac tissue and heart valves, potentially offering curative solutions.
• Artificial Intelligence and Machine Learning: Further integration of AI in automated image analysis for faster and more accurate diagnosis, prediction of treatment response, and optimization of procedural planning.
• Telemedicine and Remote Monitoring: Leveraging digital health technologies for continuous remote monitoring of patients with SHD, enabling earlier detection of decompensation and proactive management, particularly for chronic heart failure.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

9. Conclusion

Structural heart disease represents a formidable and increasingly prevalent challenge within global healthcare, encompassing a wide range of complex cardiac conditions that can profoundly compromise heart function and significantly diminish patient quality of life. From congenital anomalies manifesting at birth to acquired valvular and myocardial disorders, the intricate interplay of genetic, environmental, and lifestyle factors dictates the unique pathophysiological course of each condition. The exponential advancements in diagnostic technologies, particularly in the realm of advanced cardiac imaging such as CMRI and CCT, coupled with a revolutionary expansion of therapeutic interventions—ranging from sophisticated medical pharmacotherapies to pioneering transcatheter procedures and refined surgical techniques—have fundamentally transformed the landscape of SHD management. This paradigm shift underscores the critical importance of a meticulously integrated, multidisciplinary ‘Heart Team’ approach, ensuring that each patient receives a highly personalized treatment strategy optimized for their specific needs and risk profile.

Crucially, the overwhelming evidence consistently highlights the paramount significance of early detection and timely, decisive intervention. Identifying and addressing structural abnormalities before irreversible myocardial damage occurs or before patients become severely symptomatic is demonstrably associated with improved survival rates, a reduced incidence of debilitating complications like heart failure and life-threatening arrhythmias, and a significantly enhanced overall quality of life. As ongoing research continues to unravel the complexities of SHD at molecular and cellular levels, and as clinical trials continually refine our understanding of optimal treatment strategies, the future of structural heart disease management promises even more precise diagnostics, less invasive and more durable interventions, and a greater emphasis on personalized medicine. The continued collaborative efforts of clinicians, researchers, and innovators are pivotal in our collective endeavor to further optimize patient outcomes, alleviate the burden of SHD, and ultimately, enable affected individuals to lead healthier, more fulfilling lives.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

1. Cleveland Clinic. (n.d.). Structural Heart Disease: Types, Symptoms & Treatment. Retrieved from https://my.clevelandclinic.org/health/diseases/22501-structural-heart-disease
2. PubMed. (2019). Current status and future perspective of structural heart disease intervention. Retrieved from https://pubmed.ncbi.nlm.nih.gov/30955999/
3. Mount Sinai Health System. (n.d.). Structural Heart Disease Program. Retrieved from https://www.mountsinai.org/care/heart/services/structural-heart
4. Memorial Hermann Health System. (n.d.). Structural Heart Disease and Interventional Cardiology. Retrieved from https://memorialhermann.org/services/conditions/structural-heart-disease-and-interventional-cardiology
5. Virginia Mason Franciscan Health. (n.d.). Structural Problems – Diagnosis and Treatment. Retrieved from https://www.vmfh.org/our-services/center-for-cardiovascular-health/structural-heart/diagnosis-treatment-structural-heart-conditions
6. Yale Medicine. (n.d.). Structural Heart Disease. Retrieved from https://www.yalemedicine.org/conditions/structural-heart-disease
7. National Center for Biotechnology Information. (2017). Structural Heart Diseases. In Cardiovascular, Respiratory, and Related Disorders. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK525139/
8. Apollo 247. (n.d.). Understanding All About Structural Heart Disease. Retrieved from https://www.apollo247.com/health-topics/heart-disease/structural-heart-disease
9. Mayo Clinic. (n.d.). Structural Heart Disease Program. Retrieved from https://www.mayo.edu/research/centers-programs/cardiovascular-research-center/research/structural-heart-disease-program
10. Baptist Health. (n.d.). Structural Heart Disease Treatment. Retrieved from https://www.baptist-health.com/services/heart-health/preventative-treatments/structural-heart-disease-treatment
11. Wikipedia. (2021). Aortic stenosis. Retrieved from https://en.wikipedia.org/wiki/Aortic_stenosis
12. National Center for Biotechnology Information. (2017). Structural Heart Diseases. In Cardiovascular, Respiratory, and Related Disorders. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK525139/